Quantcast

Latest Bristol-Myers Squibb Stories

2014-06-10 12:30:30

LONDON, June 10, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Non-small cell lung cancer: Game changing immunotherapies to revolutionise treatment - KOL Insighthttp://www.reportbuyer.com/pharma_healthcare/diseases/non_small_cell_lung_cancer_game_changing_immunotherapies_revolutionise_treatment_kol_insight.html Change is coming to the NSCLC treatment algorithm--and it's coming soon. Revolutionary new immunotherapies, more personalised treatment choices...

2014-06-04 08:34:06

LONDON, June 4, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Hepatitis Drugs and Vaccines: World Market 2013-2023http://www.reportbuyer.com/pharma_healthcare/therapeutic/hepatitis_drugs_vaccines_world_market_2013_2023.html Report DetailsYour guide to sales outlooks and R&D for hepatitis treatmentsWhere are hepatitis medicines going? Visiongain's updated report predicts revenues there from 2013 to 2023. It also explains trends in that business and...

2014-06-03 11:21:00

University of Texas M. D. Anderson Cancer Center Early but promising results lead to Phase II national trial In an aggressive disease known for poor response rates, researchers from The University of Texas MD Anderson Cancer Center found patients with advanced colorectal cancer responded well to a combination therapy of the drugs vermurafenib, cetuximab and irinotecan. The Phase I trial, presented Saturday, May 31 in a poster discussion at the American Society of Clinical Oncology's...

2014-06-02 08:29:32

Phase 1 Study Evaluating Talimogene Laherparepvec Plus Ipilimumab Showed Tolerability at Doses Administered THOUSAND OAKS, Calif., June 2, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new data from two key clinical trials that support the potential of talimogene laherparepvec, a novel, investigational oncolytic immunotherapy, as both a single agent and as part of a combination regimen in patients with metastatic melanoma. The findings were presented at the 50th...

2014-05-31 08:21:10

Study Shows Improved Survival Benefit in Panitumumab Arm THOUSAND OAKS, Calif., May 31, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from the Phase 2 PEAK study that reinforce the improved overall survival (OS) benefit of panitumumab (Vectibix(®)) when used in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, compared to bevacizumab (Avastin(®)) plus FOLFOX as first-line treatment in patients with wild-type RAS metastatic colorectal cancer (mCRC). The...

2014-05-29 16:26:28

Medtronic Agrees to $9.9 Million Settlement in Cardiac Implant Kickback Case SANTA MONICA, Calif., May 29, 2014 /PRNewswire/ -- Qui Tam ("Whistleblower") attorney Mychal Wilson, Esq. announces that Medtronic, the world's largest maker of medical devices, has agreed to pay the United States $9.9 million to resolve allegations under the False Claims Act that the company used various types of payments to induce physicians to implant pacemakers and defibrillators manufactured and sold by...

2014-05-28 12:31:07

LONDON, May 28, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Pancreatic Cancer - Pipeline Review, H1 2014http://www.reportbuyer.com/pharma_healthcare/treatments/pancreatic_cancer_pipeline_review_h1_2013.html Pancreatic Cancer - Pipeline Review, H1 2014 SummaryGlobal Markets Direct's, 'Pancreatic Cancer - Pipeline Review, H1 2014', provides an overview of the Pancreatic Cancer's therapeutic pipeline.This report provides comprehensive information on...

2014-05-23 20:21:52

GERMANTOWN, Maryland and HILDEN, Germany, May 23, 2014 /PRNewswire/ -- - Clinically proven companion diagnostic gains U.S. approval to guide use of Amgen's Vectibix(R) (panitumumab) in treatment of metastatic colorectal cancer - FDA approval (PMA) of therascreen KRAS RGQ PCR Kit for Vectibix expands QIAGEN's leadership in molecular companion diagnostics for personalized healthcare - QIAGEN driving the adoption of molecular tests...

2014-05-23 16:24:12

Vectibix is the First and Only Biologic to Offer Significant Survival Benefit as a First-Line Treatment with FOLFOX Chemotherapy for Patients with Wild-Type KRAS Metastatic Colorectal Cancer THOUSAND OAKS, Calif., May 23, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Vectibix(® )(panitumumab) for use in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, as first-line treatment in patients with...

2014-05-21 12:23:02

Editor Note: For more information about this release, please scroll to bottom. LONDON, May 21, 2014 /PRNewswire/ -- The markets on Tuesday, May 20, 2014 ended on a negative note as the Dow Jones Industrial Average finished at 16,374.31, down 0.83% and the NASDAQ Composite closed at 4,096.89, down 0.70%. The S&P 500 edged 0.65% lower, to finish the day at 1,872.83. The losses were broad based as nine out of ten sectors ended the session in negative. During the session,...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related